Conference
Abstract P5-02-40: Anthracycline improves the outcome of neoadjuvant trastuzumab-treated breast cancer patients with FcγRIIIA F/F genotype by decreasing the ratios of CD8+PD1+ and CD68+PDL1+ cells
Abstract
Abstract
Background: Antibody-dependent cell-mediated cytotoxicity (ADCC) is one of the most important mechanisms of trastuzumab. Fragment C Gamma receptor (FcγR) IIA and IIIA polymorphisms influence the affinity of immunoglobin G (IgG). Recently, FcγRIIA and FcγRIIIA polymorphisms have identified with the efficacy of trastuzumab. However, whether FcγR polymorphisms are associated with the efficacy of trastuzumab in the …
Authors
Lee K; Luo R; Lu Q; Wang S; Xu F
Volume
83
Publisher
American Association for Cancer Research (AACR)
Publication Date
March 1, 2023
DOI
10.1158/1538-7445.sabcs22-p5-02-40
Conference proceedings
Cancer Research
Issue
5_Supplement
ISSN
0008-5472